German Study: CGM Cuts Dangerous Nighttime Lows in Type 1 Diabetes

A study from Germany has revealed a striking finding for people living with Type 1 diabetes: without continuous glucose monitoring (CGM), nighttime low blood sugar episodes are significantly longer and more frequent than daytime lows — but CGM technology can effectively erase that dangerous gap entirely.

What the Researchers Did

Scientists at the Research Institute of the Diabetes-Academy Mergentheim (FIDAM) re-analyzed data from the HypoDE trial, a rigorous randomized controlled trial involving 141 adults with Type 1 diabetes who either had impaired hypoglycemia awareness or a prior severe hypoglycemic event. Participants were assigned to either use a Dexcom G5 CGM device or continue traditional self-monitoring of blood glucose (finger sticks). Researchers tracked how much time patients spent in hypoglycemia and how often severe hypoglycemic events occurred.

Key Findings: The Numbers in Plain English

At the start of the study, participants not using CGM spent significantly more time in dangerous nighttime lows. Specifically, nighttime low blood sugar episodes below 54 mg/dL (equivalent to 3.0 mmol/L) lasted on average 30.7 minutes longer than daytime episodes — a medically significant difference. Nighttime hypoglycemia exposure was also 1.4 percentage points higher than daytime exposure.

For reference, the American Diabetes Association (ADA) defines a clinically significant hypoglycemic event as blood glucose below 54 mg/dL, and a hypoglycemia alert value at 70 mg/dL (3.9 mmol/L). Both thresholds were evaluated in this trial.

The good news: among patients using CGM, this nighttime-versus-daytime gap virtually disappeared. The difference in low blood sugar exposure dropped to just 0.3 percentage points — essentially negligible. Meanwhile, patients relying solely on finger-stick testing continued to show the dangerous nighttime disparity throughout the trial.

The study also found that daytime hypoglycemia significantly increased the risk of a severe hypoglycemic event — the kind requiring assistance from another person. Each additional percentage point of time spent below 70 mg/dL during the day raised severe hypoglycemia risk by 10%.

Why This Matters for US Patients

This German research carries direct relevance for the estimated 1.6 million Americans living with Type 1 diabetes. Here's why:

• Nighttime lows are silent killers. Unlike daytime lows, nocturnal hypoglycemia often goes undetected because patients are asleep and cannot feel or respond to warning symptoms. CGM devices alert patients — and caregivers — before episodes become life-threatening.
• CGM access remains unequal in the US. While Medicare now covers CGM for insulin-using patients and many private insurers follow suit, coverage gaps still exist, particularly for uninsured or underinsured Americans. This study strengthens the case for broader access.
• The daytime-to-severe hypoglycemia link is actionable. Knowing that daytime lows predict severe events gives patients and providers a clear target: reduce daytime hypoglycemia time-in-range to lower catastrophic risk.
• Impaired hypoglycemia awareness is underdiagnosed. Many Type 1 patients lose their ability to feel low blood sugar symptoms over time. This study specifically included that population — a group that arguably benefits most from CGM technology.

Bottom Line

German researchers have provided compelling, controlled evidence that CGM doesn't just improve convenience — it fundamentally changes the safety profile of living with Type 1 diabetes, particularly during the vulnerable overnight hours. If you or a loved one has Type 1 diabetes, especially with a history of severe lows or reduced hypoglycemia awareness, talk to your endocrinologist about CGM coverage options available to you today.

Original study: Hermanns, Heinemann, Kulzer. "Continuous glucose monitoring as equinox of nocturnal and daytime hypoglycaemia in type 1 diabetes: insights from the randomized controlled HypoDE trial." Diabetes Research and Clinical Practice, 2025. DOI: 10.1016/j.diabres.2025.112228. PMID: 40348338.